Acarbose

Limits on what this shows

• Why no grade: No Tier B or Tier C evidence linking acarbose, or the alpha-glucosidase-inhibitor class, to mitochondrial structure, membrane integrity, electron transport, or biogenesis was found across multiple Crossref query phrasings ("acarbose mitochondria," "alpha-glucosidase inhibitor mitochondrial biogenesis reactive oxygen species"). No circulating consumer claim about acarbose and mitochondrial burden was identified within the channels reachable this session. Both conditions for ungraded are met.

Tooling note

This session's WebSearch allowance was exhausted before this category could be cross-checked against general web sources (this is medication 19 of 25 in a shared batch); DailyMed, NCBI Bookshelf, and Crossref remained reachable and were queried directly instead. A revision should re-run this category once WebSearch capacity resets.

Prior plausibility

Low: under 2% systemic absorption argues against a meaningful systemic mitochondrial exposure regardless of what a future search might find.

Limits on what this shows

• Key negative/null findings: No dedicated human RCT measuring a validated oxidative-stress biomarker (e.g. MDA, 8-iso-PGF2alpha, nitrotyrosine) specifically in acarbose-treated patients was located in this review, despite targeted searches; this is a genuine human-evidence gap layered onto a Tier B animal finding, not a confirmed human effect.
• At-risk subgroups: Not established; findings are from a single rodent strain and dietary model.

Regulatory status

Not addressed in the FDA label.

Population evidence

Young Zucker rats with impaired glucose tolerance, acarbose-treated vs untreated. Acarbose diminished oxidative stress markers relative to untreated impaired-glucose-tolerance controls. Rosen and Osmers, Hormone and Metabolic Research 2006, DOI 10.1055/s-2006-950397. Tier B (animal, this drug in the cohort).

Mechanism

Acute hyperglycemic excursions are an established driver of oxidative stress in general diabetes physiology (Ceriello and colleagues, class-level mechanistic literature, not acarbose-specific); acarbose's established, label-confirmed pharmacologic effect of blunting postprandial glucose rise provides a plausible route by which it could secondarily lower glucose-driven oxidative stress. This mechanism is protective/reverse-direction, not a depletion pathway.

Counter-evidence held on record

This is Tier B, single-study, animal-only evidence; it should not be extrapolated to a confirmed human antioxidant benefit. Because the direction is protective, not depleting, it must never be presented as a reason to add antioxidant supplements alongside acarbose; if anything, the finding argues against a supplementation rationale.

Limits on what this shows

• Why no grade: Crossref queries ("acarbose copper ceruloplasmin") returned no drug-relevant results. No circulating consumer claim about acarbose and copper status was identified within the channels reachable this session. Both conditions for ungraded are met.

Tooling note

Same WebSearch-budget limitation as above; DailyMed and Crossref were checked directly and returned nothing.

Prior plausibility

Low: no chelation, gastric-pH, or transporter-competition mechanism for copper is documented or plausible for a drug that acts by inhibiting carbohydrate-digesting enzymes within the gut lumen.

Limits on what this shows

• Why no grade: Crossref queries ("acarbose iron ferritin anemia") returned no drug-relevant results. No circulating consumer claim about acarbose and iron status was identified within the channels reachable this session. Both conditions for ungraded are met.

Tooling note

Same WebSearch-budget limitation as above; DailyMed and Crossref were checked directly and returned nothing. Note this is distinct from, and should not be confused with, the graded Oxygen delivery/utilization (hematocrit) entry above, which is a measured hematologic lab value, not an iron-status measure; iron studies (ferritin, transferrin saturation) specifically were not found.

Prior plausibility

Low, for the same reason as copper.

Limits on what this shows

• Population evidence (null): Randomized, placebo-controlled, double-blind crossover trial, 15 patients with type 2 diabetes already on metformin, 14-day treatment periods. Overall gut microbiome profile "remained unaffected" by acarbose vs placebo, with no significant change in diversity or composition; a minor increase in Klebsiella and Escherichia coli was the only notable shift. Dalsgaard et al., Endocrine Connections 2024, DOI 10.1530/EC-24-0052.
• At-risk subgroups: Effect (where present) appears diet-dependent in humans (Ozaki et al. found dietary macronutrient pattern predicted which taxa moved); no subgroup data on effect in inflammatory bowel disease or short-bowel patients, who are separately contraindicated for acarbose on other grounds.

Regulatory status

Not addressed in the FDA label. Mechanistically plausible: acarbose blocks small-intestinal carbohydrate digestion, delivering more undigested carbohydrate to the colon, which is fermented by resident bacteria (this is also the documented mechanism behind acarbose's flatulence and diarrhea, at 74% and 31% vs 29% and 12% on placebo in the label).

Population evidence (positive)

Open-label, single-arm pilot, 18 Japanese patients with type 2 diabetes, 4 weeks of acarbose (150 or 300 mg/day). Significant genus-level increases in Bifidobacterium, Eubacterium, and Lactobacillus, and decreases in Bacteroides, Blautia, and Prevotella (p<0.05), with taxa changes correlating with habitual diet. Ozaki et al., Nutrients 2021, PMID 34205413.

Mechanism / longer-term animal data

In genetically heterogeneous HET3 mice (n=144, 3 independent aging-research sites), long-term acarbose produced a large, reproducible shift toward a single Muribaculaceae taxon (relative abundance roughly tripling to quadrupling, p<0.001-0.007 across sites) and a consistent rise in fecal propionate, which together were statistically linked to the drug's lifespan-extension effect. Direction is protective/beneficial, not depleting. Smith et al., BMC Microbiology 2019, DOI 10.1186/s12866-019-1494-7.

Counter-evidence held on record

The two human studies conflict, and the better-designed one (randomized, placebo-controlled, blinded, crossover) found no significant effect over two weeks, while the positive finding comes from an uncontrolled 18-person pilot. The label of "gut microbiome risk" should not be read as established harm: the best long-term (animal) evidence associates the acarbose-driven shift with a beneficial, short-chain-fatty-acid-producing profile linked to longevity, not dysbiosis. An active-comparator limitation applies to none of these (placebo-controlled), but exposure duration in the negative human trial (14 days) may be too short to detect an effect that the positive pilot saw at 4 weeks.

Limits on what this shows

• Key negative/null findings: Hemoglobin itself was not reduced, which argues against a clinically meaningful reduction in oxygen-carrying capacity per unit of blood.
• At-risk subgroups: Not specified in the label; no stratification by age, sex, dose, or duration was available in the public label text.

Regulatory status

Disclosed in the FDA-approved label's "Other Abnormal Laboratory Findings" subsection of Adverse Reactions.

Population evidence

FDA-reviewed pooled analysis of the PRECOSE pivotal U.S. clinical trial program (acarbose 50-300 mg t.i.d. vs placebo). Exact incidence, magnitude, and confidence interval are not broken out numerically in the publicly available label text; the finding is stated qualitatively as occurring "more often" with acarbose.

Mechanism

Not named in the label. Plausible candidates include mild hemodilution or a laboratory/measurement artifact; no GI blood loss, hemolysis, or marrow-suppression mechanism is documented for acarbose specifically.

Counter-evidence held on record

This is a real, drug-specific, Tier A signal from the sponsor's own trial program, which is why it clears orange rather than sitting at yellow. But without hemoglobin change, a magnitude, or a named mechanism, it should not be read as an anemia risk or as a call for iron or B12 repletion. Type 2 diabetes itself carries a modestly elevated background rate of subclinical hematologic changes, so confounding by indication has not been excluded here. This is a lab-value observation, not an established clinical anemia outcome, and it is not the drug's intended pharmacologic effect (Hard Rule 2 check: acarbose's intended effect is glycemic, not hematologic).

Limits on what this shows

• Why no grade: No Tier B or Tier C evidence linking acarbose, or the alpha-glucosidase-inhibitor class, to mitochondrial ATP synthesis or cellular energy output was found across multiple Crossref query phrasings ("acarbose ATP production cellular energy," "acarbose ATP skeletal muscle energy metabolism"). No circulating consumer claim was identified within the channels reachable this session. Both conditions for ungraded are met.

Disclosed but unused claim

A Tier B secondary reference (StatPearls) makes an isolated, uncited assertion that acarbose "may decrease skeletal muscle index and grip strength." Multiple targeted Crossref searches for a primary source (sarcopenia, grip strength, skeletal muscle index, alpha-glucosidase inhibitors) found no matching study. This claim could not be traced to verifiable primary evidence in this review and is disclosed here rather than used to support any grade.

Tooling note

Same WebSearch-budget limitation as above.